<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1217" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1217/" /><meta name="ncbi_pagename" content="Urea Cycle Disorders Overview - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Urea Cycle Disorders Overview - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Urea Cycle Disorders Overview" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/06/22" /><meta name="citation_author" content="Nicholas Ah Mew" /><meta name="citation_author" content="Kara L Simpson" /><meta name="citation_author" content="Andrea L Gropman" /><meta name="citation_author" content="Brendan C Lanpher" /><meta name="citation_author" content="Kimberly A Chapman" /><meta name="citation_author" content="Marshall L Summar" /><meta name="citation_pmid" content="20301396" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1217/" /><meta name="citation_keywords" content="Citrullinemia Type I" /><meta name="citation_keywords" content="Carbamoylphosphate Synthetase I Deficiency" /><meta name="citation_keywords" content="Ornithine Transcarbamylase Deficiency" /><meta name="citation_keywords" content="Argininosuccinate Lyase Deficiency" /><meta name="citation_keywords" content="Arginase Deficiency" /><meta name="citation_keywords" content="N-Acetylglutamate Synthase Deficiency" /><meta name="citation_keywords" content="Arginase-1" /><meta name="citation_keywords" content="Argininosuccinate lyase" /><meta name="citation_keywords" content="Argininosuccinate synthase" /><meta name="citation_keywords" content="Carbamoyl-phosphate synthase [ammonia], mitochondrial" /><meta name="citation_keywords" content="N-acetylglutamate synthase, mitochondrial" /><meta name="citation_keywords" content="Ornithine carbamoyltransferase, mitochondrial" /><meta name="citation_keywords" content="ARG1" /><meta name="citation_keywords" content="ASL" /><meta name="citation_keywords" content="ASS1" /><meta name="citation_keywords" content="CPS1" /><meta name="citation_keywords" content="NAGS" /><meta name="citation_keywords" content="OTC" /><meta name="citation_keywords" content="Urea Cycle Disorders" /><meta name="citation_keywords" content="Overview" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Urea Cycle Disorders Overview" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Nicholas Ah Mew" /><meta name="DC.Contributor" content="Kara L Simpson" /><meta name="DC.Contributor" content="Andrea L Gropman" /><meta name="DC.Contributor" content="Brendan C Lanpher" /><meta name="DC.Contributor" content="Kimberly A Chapman" /><meta name="DC.Contributor" content="Marshall L Summar" /><meta name="DC.Date" content="2017/06/22" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1217/" /><meta name="description" content="The goals of this overview on urea cycle disorders are the following:" /><meta name="og:title" content="Urea Cycle Disorders Overview" /><meta name="og:type" content="book" /><meta name="og:description" content="The goals of this overview on urea cycle disorders are the following:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1217/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ucd-overview/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1217/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D374EE040FC0100000000049401AD.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1217_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1217_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/epm1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/urofacial/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1217_"><span class="title" itemprop="name">Urea Cycle Disorders Overview</span></h1><p class="contrib-group"><span itemprop="author">Nicholas Ah Mew</span>, MD, <span itemprop="author">Kara L Simpson</span>, MS, CGC, <span itemprop="author">Andrea L Gropman</span>, MD, <span itemprop="author">Brendan C Lanpher</span>, MD, <span itemprop="author">Kimberly A Chapman</span>, MD, PhD, and <span itemprop="author">Marshall L Summar</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1217_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1217_ai__"><div class="contrib half_rhythm"><span itemprop="author">Nicholas Ah Mew</span>, MD<div class="affiliation small">Children&#x02019;s National Rare Disease Institute<br />Children&#x02019;s National Health System<br />Washington, DC<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.lanoitansnerdlihc@wemhan" class="oemail">gro.lanoitansnerdlihc@wemhan</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Kara L Simpson</span>, MS, CGC<div class="affiliation small">Children&#x02019;s National Rare Disease Institute<br />Children&#x02019;s National Health System<br />Washington, DC<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.lanoitansnerdlihc@nospmisk" class="oemail">gro.lanoitansnerdlihc@nospmisk</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Andrea L Gropman</span>, MD<div class="affiliation small">Department of Pediatrics<br />Division of Neurology<br />Children&#x02019;s National Health System<br />Washington, DC<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.lanoitansnerdlihc@namporga" class="oemail">gro.lanoitansnerdlihc@namporga</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Brendan C Lanpher</span>, MD<div class="affiliation small">Department of Clinical Genomics<br />Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@nadnerb.rehpnal" class="oemail">ude.oyam@nadnerb.rehpnal</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Kimberly A Chapman</span>, MD, PhD<div class="affiliation small">Children&#x02019;s National Rare Disease Institute<br />Children&#x02019;s National Health System<br />Washington, DC<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.lanoitansnerdlihc@nampahck" class="oemail">gro.lanoitansnerdlihc@nampahck</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Marshall L Summar</span>, MD<div class="affiliation small">Children&#x02019;s National Rare Disease Institute<br />Children&#x02019;s National Health System<br />Washington, DC<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.lanoitansnerdlihc@rammusm" class="oemail">gro.lanoitansnerdlihc@rammusm</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">April 29, 2003</span>; Last Update: <span itemprop="dateModified">June 22, 2017</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ucd-overview.Summary" itemprop="description"><h2 id="_ucd-overview_Summary_">Summary</h2><p>The goals of this overview on urea cycle disorders are the following:</p><div><h4 class="inline">Goal 1.</h4><p>To define the <a href="#ucd-overview.Definition">urea cycle</a> and to describe the <a href="#ucd-overview.Clinical_Characteristics">clinical characteristics</a> of urea cycle disorders</p></div><div><h4 class="inline">Goal 2.</h4><p>To review the <a href="#ucd-overview.Specific_Urea_Cycle_Disorde">causes</a> of urea cycle disorders and their <a href="#ucd-overview.Prevalence_of_Urea_Cycle_Di">prevalence</a></p></div><div><h4 class="inline">Goal 3.</h4><p>To provide an <a href="#ucd-overview.Evaluation_Strategy_to_Iden">evaluation strategy</a> to identify the specific type and genetic cause of a urea cycle defect in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></p></div><div><h4 class="inline">Goal 4.</h4><p>To review the <a href="#ucd-overview.Differential_Diagnosis_of_U">differential diagnosis</a> of urea cycle disorders</p></div><div><h4 class="inline">Goal 5.</h4><p>To inform <a href="#ucd-overview.Genetic_Risk_Assessment_in">genetic risk assessment</a> in family members of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></p></div><div><h4 class="inline">Goal 6.</h4><p>To provide a brief summary of the <a href="#ucd-overview.Acute_Management_of_a_Urea">acute management</a> of a urea cycle disorder</p></div></div><div id="ucd-overview.Definition_of_the_Urea_Cycl"><h2 id="_ucd-overview_Definition_of_the_Urea_Cycl_">Definition of the Urea Cycle and Clinical Characteristics of Urea Cycle Disorders</h2><div id="ucd-overview.Definition"><h3>Definition</h3><p>The urea cycle:</p><ul><li class="half_rhythm"><div>Is the sole source of endogenous production of arginine, ornithine, and citrulline;</div></li><li class="half_rhythm"><div>Is the principal mechanism for the clearance of waste nitrogen resulting from protein turnover;</div></li><li class="half_rhythm"><div>Is the principal mechanism for the metabolism of other nitrogenous metabolic compounds such as adenosine monophosphate;</div></li><li class="half_rhythm"><div>Includes enzymes that overlap with the nitric oxide production pathway (ASS1 and ASL).</div></li></ul><p>The urea cycle comprises the following (<a class="figpopup" href="/books/NBK1217/figure/ucd-overview.F1/?report=objectonly" target="object" rid-figpopup="figucdoverviewF1" rid-ob="figobucdoverviewF1">Figure 1</a>) [<a class="bk_pop" href="#ucd-overview.REF.krebs.1932.325">Krebs &#x00026; Henseleit 1932</a>]:</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figucdoverviewF1" co-legend-rid="figlgnducdoverviewF1"><a href="/books/NBK1217/figure/ucd-overview.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figucdoverviewF1" rid-ob="figobucdoverviewF1"><img class="small-thumb" src="/books/NBK1217/bin/ucd-overview-Image001.gif" src-large="/books/NBK1217/bin/ucd-overview-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgnducdoverviewF1"><h4 id="ucd-overview.F1"><a href="/books/NBK1217/figure/ucd-overview.F1/?report=objectonly" target="object" rid-ob="figobucdoverviewF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">The urea cycle </p></div></div><ul><li class="half_rhythm"><div>Five catalytic enzymes:</div><ul><li class="half_rhythm"><div>Carbamoylphosphate synthetase I (CPS1)</div></li><li class="half_rhythm"><div>Ornithine transcarbamylase (OTC)</div></li><li class="half_rhythm"><div>Argininosuccinic acid synthetase (ASS1)</div></li><li class="half_rhythm"><div>Argininosuccinic acid lyase (ASL)</div></li><li class="half_rhythm"><div>Arginase (ARG1)</div></li></ul></li><li class="half_rhythm"><div>One cofactor-producing enzyme: N-acetyl glutamate synthetase (NAGS)</div></li><li class="half_rhythm"><div>Two amino acid transporters:</div><ul><li class="half_rhythm"><div>Ornithine translocase (ORNT1; ornithine/citrulline carrier; solute carrier family 25, member 15)</div></li><li class="half_rhythm"><div>Citrin (aspartate/glutamate carrier; solute carrier family 25, member 13)</div></li></ul></li></ul><p>Urea cycle disorders (UCDs) result from inherited deficiencies in any one of the six enzymes or two transporters of the urea cycle pathway (CPS1, OTC, ASS1, ASL, ARG1, NAGS, ORNT1, or citrin).</p></div><div id="ucd-overview.Clinical_Characteristics"><h3>Clinical Characteristics</h3><p>Severity of the urea cycle defect is influenced by the position of the defective protein in the pathway and the severity of the defect (see <a class="figpopup" href="/books/NBK1217/figure/ucd-overview.F1/?report=objectonly" target="object" rid-figpopup="figucdoverviewF1" rid-ob="figobucdoverviewF1">Figure 1</a>).</p><p><b>Severe deficiency or total absence of activity</b> of any of the first four enzymes in the pathway (CPS1, OTC, ASS1, and ASL) or the cofactor producer (NAGS) results in the accumulation of ammonia and other precursor metabolites during the first few days of life. Because no effective secondary clearance system for ammonia exists, complete disruption of this pathway results in the rapid accumulation of ammonia and development of related symptoms.</p><p><b>Presentation.</b> Individuals with complete defects normally present in the newborn period, when the immaturity of the neonatal liver accentuates defects in the urea cycle enzymes [<a class="bk_pop" href="#ucd-overview.REF.pearson.2001.1832">Pearson et al 2001</a>, <a class="bk_pop" href="#ucd-overview.REF.summar.2001">Summar 2001</a>, <a class="bk_pop" href="#ucd-overview.REF.summar.2001.s6">Summar &#x00026; Tuchman 2001</a>].</p><ul><li class="half_rhythm"><div>Infants with a urea cycle disorder appear normal at birth but rapidly develop cerebral edema and the related signs of lethargy, anorexia, hyper- or hypoventilation, hypothermia, seizures, neurologic posturing, and coma.</div></li><li class="half_rhythm"><div>Because newborns are usually discharged from the hospital within one to two days after birth, the symptoms of a urea cycle disorder often develop when the child is at home and may not be recognized in a timely manner by the family and primary care physician.</div></li></ul><p><b>The typical initial symptoms</b> of a child with hyperammonemia are nonspecific [<a class="bk_pop" href="#ucd-overview.REF.summar.2001">Summar 2001</a>, <a class="bk_pop" href="#ucd-overview.REF.k_lker.2015.1041">K&#x000f6;lker et al 2015</a>]:</p><ul><li class="half_rhythm"><div>Failure to feed</div></li><li class="half_rhythm"><div>Loss of thermoregulation with a low core temperature</div></li><li class="half_rhythm"><div>Somnolence</div></li></ul><p><b>Symptoms progress</b> from somnolence to lethargy and coma.</p><ul><li class="half_rhythm"><div>Abnormal posturing and encephalopathy are often related to the degree of central nervous system swelling and pressure on the brain stem [<a class="bk_pop" href="#ucd-overview.REF.summar.2001">Summar 2001</a>].</div></li><li class="half_rhythm"><div>About 50% of neonates with severe hyperammonemia may have seizures, some without overt clinical manifestations.</div></li><li class="half_rhythm"><div>Individuals with closed cranial sutures are at higher risk for rapid neurologic deterioration from the cerebral edema that results from ammonia elevation.</div></li><li class="half_rhythm"><div>Hyperventilation secondary to the effect of hyperammonemia on the brain stem, a common early finding in hyperammonemic attacks, results in respiratory alkalosis.</div></li><li class="half_rhythm"><div>Hypoventilation and respiratory arrest follow as pressure increases on the brain stem.</div></li></ul><p><b>In milder (or partial) urea cycle enzyme deficiencies,</b> ammonia accumulation may be triggered at almost any time of life by illness or stress (e.g., surgery, prolonged fasting, holidays, the peripartum period), resulting in multiple mild elevations of plasma ammonia concentration.</p><ul><li class="half_rhythm"><div>Hyperammonemia in the milder defects is typically less severe and the symptoms more subtle than the neonatal presentation of a UCD.</div></li><li class="half_rhythm"><div>In individuals with partial enzyme deficiencies, the first recognized clinical episode may be delayed for months or years.</div></li><li class="half_rhythm"><div>Although the clinical abnormalities vary somewhat with the specific urea cycle disorder, in most the hyperammonemic episode is marked by loss of appetite, vomiting, lethargy, and behavioral abnormalities [<a class="bk_pop" href="#ucd-overview.REF.gardeitchik.2012.328">Gardeitchik et al 2012</a>].</div></li><li class="half_rhythm"><div>Sleep disorders, delusions, hallucinations, and psychosis may occur.</div></li><li class="half_rhythm"><div>An encephalopathic (slow-wave) EEG pattern may be observed during hyperammonemia and nonspecific brain atrophy seen subsequently on MRI.</div></li></ul><p><b>Defects in the final enzyme in the pathway (ARG1)</b> cause hyperargininemia, a more subtle disorder involving neurologic symptoms; however, neonatal hyperammonemia has been reported (see <a href="/books/n/gene/arg1/">Arginase Deficiency</a>).</p><p><b>Defects in the two amino acid transporters (ORNT1 and citrin deficiency)</b> may both cause hyperammonemia. However, ORNT1 deficiency may also present with chronic liver dysfunction. Citrin deficiency typically only presents with hyperammonemia in adolescence or adulthood, but may present in infants with neonatal intrahepatic cholestasis, and in older children with failure to thrive.</p><p><b>Neurologic aspects of UCDs.</b> Ammonia can cause brain damage through a variety of proposed mechanisms, a major component of which is cerebral edema through increased glutamine. The specific roles of ammonia, glutamate, and glutamine in cerebral edema are still under investigation [<a class="bk_pop" href="#ucd-overview.REF.gropman.2007.865">Gropman et al 2007</a>, <a class="bk_pop" href="#ucd-overview.REF.lichterkonecki.2008.492">Lichter-Konecki 2008</a>, <a class="bk_pop" href="#ucd-overview.REF.lichterkonecki.2008.365">Lichter-Konecki et al 2008</a>, <a class="bk_pop" href="#ucd-overview.REF.albrecht.2010.1303">Albrecht et al 2010</a>, <a class="bk_pop" href="#ucd-overview.REF.braissant.2013.595">Braissant et al 2013</a>].</p><p>Damage resulting from acute hyperammonemia in infancy resembles that seen in hypoxic-ischemic events or stroke. The most vulnerable areas are the insular cortex, which represents deep white matter. With prolonged hyperammonemia, the parietal, occipital, and frontal regions are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. This is best appreciated on T<sub>2</sub>-weighted MRI sequences or on diffusion tensor imaging.</p><p>Neuroimaging may be helpful in identifying <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> areas of the brain. However, MRI findings may lag behind clinical changes. In fact, early imaging may be normal as some degree of injury must occur before macroscopic changes are seen on MRI.</p><p>Chronic hyperammonemia may disrupt ion-gradients and neurotransmitters, transport of metabolites, mitochondrial function, and the alpha-ketoglutarate/ glutamate/glutamine ratio.</p><p>Seizures are common in acute hyperammonemia and may result from cerebral damage. Recent findings suggest that subclinical seizures are common in acute hyperammonemic episodes, especially in neonates, and their effects on cerebral metabolism in an otherwise compromised state should be addressed (see Management, <a href="#ucd-overview.Treatment_of_Acute_Manifest">Treatment of Acute Manifestations</a>). These seizures may be seen during the rise of glutamine even before ammonia levels are maximal [Wiwattanadittakul et al, in press].</p><p><b>Survival and intellectual outcome.</b> Historically the outcome of newborns with hyperammonemia was considered poor [<a class="bk_pop" href="#ucd-overview.REF.brusilow.1995.293">Brusilow 1995</a>]. With rapid identification and current treatment strategies, survival of neonates with hyperammonemia has improved dramatically in the last few decades. See <a class="bk_pop" href="#ucd-overview.REF.summar.2001">Summar [2001]</a>, <a class="bk_pop" href="#ucd-overview.REF.summar.2001.s6">Summar &#x00026; Tuchman [2001]</a>, <a class="bk_pop" href="#ucd-overview.REF.enns.2007.2282">Enns et al [2007]</a>, <a class="bk_pop" href="#ucd-overview.REF.summar.2008.1420">Summar et al [2008]</a>, <a class="bk_pop" href="#ucd-overview.REF.tuchman.2008.397">Tuchman et al [2008]</a>, and <a class="bk_pop" href="#ucd-overview.REF.krivitzky.2009.96">Krivitzky et al [2009]</a>.</p><p>More recent data from the NIH-sponsored longitudinal study on patients treated with the more recent protocols show IQ measures within a less severe range as summarized in <a class="figpopup" href="/books/NBK1217/table/ucd-overview.T.cognitive_and_adaptive_ou/?report=objectonly" target="object" rid-figpopup="figucdoverviewTcognitiveandadaptiveou" rid-ob="figobucdoverviewTcognitiveandadaptiveou">Table 1</a>.</p><div id="ucd-overview.T.cognitive_and_adaptive_ou" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Cognitive and Adaptive Outcome in Children with UCD Age 3-16 Years</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1217/table/ucd-overview.T.cognitive_and_adaptive_ou/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ucd-overview.T.cognitive_and_adaptive_ou_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Age Group</th><th id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Age 3-5 Years</th><th id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Age 6-16 Years</th></tr><tr><th headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1" id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_1" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Age at Onset</th><th headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2" id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neonatal&#x000a0;<sup>1</sup><br />(n=5)</th><th headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2" id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Late&#x000a0;<sup>2</sup><br />(n=7)</th><th headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3" id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neonatal&#x000a0;<sup>1</sup><br />(n=8)</th><th headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3" id="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Late&#x000a0;<sup>2</sup><br />(n=39)</th></tr></thead><tbody><tr><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Assessment</b></td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><b>WASI/WPPSI-III&#x000a0;<sup>3</sup></b><br /><b>composite scores&#x000a0;<sup>4</sup> (SD)</b></td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Verbal IQ</b></td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">81.3 (16.6)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">101.7 (24.4)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">72.9 (14.3)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">94.3 (21.7)</td></tr><tr><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Performance IQ</b></td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">77.7 (15.0)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95.6 (17.4)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">74.4 (11.7)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">89.5 (20.4)</td></tr><tr><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Full scale IQ</b></td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">77.7 (16.3)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99.6 (22.6)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">71.4 (12.8)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">94.1 (22.0)</td></tr><tr><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_1 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>ABAS-II&#x000a0;<sup>5</sup> general adaptive composite&#x000a0;<sup>4</sup> (SD)</b></td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">73.2 (31.2)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_2 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">91.4 (23.6)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">66.0 (17.9)</td><td headers="hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_1_3 hd_h_ucd-overview.T.cognitive_and_adaptive_ou_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">84.4 (21.6)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#ucd-overview.REF.krivitzky.2009.96">Krivitzky et al [2009]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">SD = standard deviation</p></div></dd><dt>1. </dt><dd><div id="ucd-overview.TF.1.1"><p class="no_margin">Clinical presentation in 1st month</p></div></dd><dt>2. </dt><dd><div id="ucd-overview.TF.1.2"><p class="no_margin">Clinical onset after 1st month or diagnosis based on family history</p></div></dd><dt>3. </dt><dd><div id="ucd-overview.TF.1.3"><p class="no_margin">Wechsler Abbreviated Scales of Intelligence / Wechsler Preschool and Primary Scale of Intelligence, 3rd Edition</p></div></dd><dt>4. </dt><dd><div id="ucd-overview.TF.1.4"><p class="no_margin">Clinically significant difference between groups for cognitive and adaptive outcome</p></div></dd><dt>5. </dt><dd><div id="ucd-overview.TF.1.5"><p class="no_margin">Adaptive Behavior Assessment System, 2nd Edition</p></div></dd></dl></div></div></div><p>While hyperammonemia is thought to be the main contributor to brain damage in UCDs, other factors, such as adverse effects on the nitric oxide production system [<a class="bk_pop" href="#ucd-overview.REF.nagamani.2012.836">Nagamani et al 2012</a>], may also contribute. For instance, neonates with CPS1 deficiency or OTC deficiency have more severe hyperammonemia than those with ASS1 deficiency or ASL deficiency; however, their intellectual outcomes appear similar [<a class="bk_pop" href="#ucd-overview.REF.ah_mew.2013.324">Ah Mew et al 2013</a>].</p><p>In a recent study, asymptomatic female carriers of OTC deficiency demonstrated no significant differences in cognitive function compared to control participants until they were cognitively challenged with fine motor tasks, measures of executive function, and measures of cognitive flexibility [<a class="bk_pop" href="#ucd-overview.REF.sprouse.2014.136">Sprouse et al 2014</a>].</p></div></div><div id="ucd-overview.Causes_of_Urea_Cycle_Disord"><h2 id="_ucd-overview_Causes_of_Urea_Cycle_Disord_">Causes of Urea Cycle Disorders (UCDs) and Prevalence</h2><div id="ucd-overview.Specific_Urea_Cycle_Disorde"><h3>Specific Urea Cycle Disorders</h3><p><b>N-acetylglutamate synthase deficiency (NAGS deficiency</b>) has been described in a number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Symptoms mimic those of CPS1 deficiency, as CPS1 is rendered inactive in the absence of N-acetylglutamate [<a class="bk_pop" href="#ucd-overview.REF.caldovic.2003.364">Caldovic et al 2003</a>].</p><p><b>Carbamoylphosphate synthetase I deficiency (CPS1 deficiency)</b> is the most severe of the urea cycle disorders. Individuals with complete CPS1 deficiency rapidly develop hyperammonemia in the newborn period. Children who are successfully rescued from crisis are chronically at risk for repeated bouts of hyperammonemia.</p><p><a href="/books/n/gene/otc-def/"><b>Ornithine transcarbamylase deficiency</b></a>
<b>(OTC deficiency).</b> Absence of OTC activity in males is as severe as CPS1 deficiency. Approximately 15% of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> females develop hyperammonemia during their lifetime and many require chronic medical management for hyperammonemia. More recently it has been recognized that carrier females who have never had symptoms of overt hyperammonemia have deficiencies in executive function.</p><p><a href="/books/n/gene/ctlm/"><b>Citrullinemia type I</b></a>
<b>(ASS1 deficiency).</b> The hyperammonemia in this disorder can also be quite severe. Affected individuals are able to incorporate some waste nitrogen into urea cycle intermediates, which makes treatment slightly easier than in the other UCDs.</p><p><a href="/books/n/gene/args-aciduria/"><b>Argininosuccinic aciduria</b></a>
<b>(</b><a href="/books/n/gene/args-aciduria/"><b>ASL deficiency</b></a><b>)</b> can also present with rapid-onset hyperammonemia in the newborn period. This enzyme defect is past the point in the metabolic pathway at which all the waste nitrogen has been incorporated into the cycle. Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop chronic hepatic enlargement and elevation of transaminases. Liver biopsy shows enlarged hepatocytes, which may over time progress to fibrosis, the etiology of which is unclear. Affected individuals can also develop trichorrhexis nodosa, a node-like appearance of fragile hair that usually responds to arginine supplementation. Affected individuals who have never had prolonged coma nevertheless have been reported to have significant developmental disabilities [<a class="bk_pop" href="#ucd-overview.REF.summar.2001">Summar 2001</a>, <a class="bk_pop" href="#ucd-overview.REF.summar.2001.s6">Summar &#x00026; Tuchman 2001</a>, <a class="bk_pop" href="#ucd-overview.REF.nagamani.2012.836">Nagamani et al 2012</a>].</p><p><a href="/books/n/gene/arg1/"><b>Arginase deficiency</b></a>
<b>(hyperargininemia, ARG1 deficiency)</b> is not typically characterized by rapid-onset hyperammonemia, however, some individuals present earlier with more severe symptoms [<a class="bk_pop" href="#ucd-overview.REF.jainghai.2011.107">Jain-Ghai et al 2011</a>]. Affected individuals develop progressive spasticity and can also develop tremor, ataxia, and choreoathetosis. Growth is also affected [<a class="bk_pop" href="#ucd-overview.REF.cederbaum.2004.s38">Cederbaum et al 2004</a>].</p><p><a href="/books/n/gene/hhhs/"><b>Ornithine translocase deficiency</b></a>
<b>(ORNT1 deficiency,</b>
<b>hyperornithinemia-hyperammonemia-homocitrullinuria syndrome)</b> has a variable age of onset ranging from infancy to adulthood. Clinical presentation can be with chronic neurocognitive deficits, hyperammonemic crisis, or chronic liver dysfunction.</p><p><a href="/books/n/gene/citrin/"><b>Citrin deficiency</b></a> can manifest in newborns as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2).</p></div><div id="ucd-overview.Prevalence_of_Urea_Cycle_Di"><h3>Prevalence of Urea Cycle Disorders</h3><p>The incidence of UCDs is estimated to be at least 1:35,000 births; partial defects may make the number much higher.</p><div id="ucd-overview.T.estimated_incidence_of_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Estimated Incidence of Individual Urea Cycle Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1217/table/ucd-overview.T.estimated_incidence_of_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ucd-overview.T.estimated_incidence_of_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urea Cycle Disorder</th><th id="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Estimated Incidence</th></tr></thead><tbody><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NAGS deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1:2,000,000</td></tr><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CPS1 deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:1,300,000</td></tr><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OTC deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:56,500</td></tr><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ASS1 deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:250,000</td></tr><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ASL deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:218,750</td></tr><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ARG1 deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:950,000</td></tr><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ornithine translocase deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Citrin deficiency</td><td headers="hd_h_ucd-overview.T.estimated_incidence_of_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:100,000-1:230,000 in Japan&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#ucd-overview.REF.lu.2005.338">Lu et al [2005]</a>, <a class="bk_pop" href="#ucd-overview.REF.kobayashi.2006.1047">Kobayashi et al [2006]</a>, <a class="bk_pop" href="#ucd-overview.REF.tabata.2008.534">Tabata et al [2008]</a>, <a class="bk_pop" href="#ucd-overview.REF.lee.2011.983">Lee et al [2011]</a>, <a class="bk_pop" href="#ucd-overview.REF.summar.2013.179">Summar et al [2013]</a></p></div></dd><dt>1. </dt><dd><div id="ucd-overview.TF.2.1"><p class="no_margin">Incidence elsewhere is unknown. However, published <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency in East Asia ranges from 1:48 to 1:112, higher than expected given incidence data.</p></div></dd></dl></div></div></div></div></div><div id="ucd-overview.Evaluation_Strategy_to_Iden"><h2 id="_ucd-overview_Evaluation_Strategy_to_Iden_">Evaluation Strategy to Identify the Specific Type and Genetic Cause of a Urea Cycle Disorder in a Proband</h2><p>The diagnosis of a urea cycle disorder (UCD) in a symptomatic individual is based on clinical, biochemical, and molecular genetic data.</p><p><b>Family history</b>. A three-generation family history with attention to other relatives (particularly children) with neurologic signs and symptoms suggestive of UCD should be obtained. Documentation of relevant findings in relatives can be accomplished either through direct examination of those individuals or review of their medical records including the results of biochemical testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, and autopsy examination. A family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance suggests <a href="/books/n/gene/otc-def/">OTC deficiency</a>.</p><p><b>Physical examination.</b> No findings on physical examination distinguish among the eight types of urea cycle defect; however, trichorrhexis nodosa can be suggestive of <a href="/books/n/gene/args-aciduria/">ASL deficiency</a> and progressive spasticity of the lower extremities suggestive of <a href="/books/n/gene/arg1/">arginase deficiency</a>.</p><div id="ucd-overview.Biochemical_Testing"><h3>Biochemical Testing</h3><p>The algorithm in <a class="figpopup" href="/books/NBK1217/figure/ucd-overview.F2/?report=objectonly" target="object" rid-figpopup="figucdoverviewF2" rid-ob="figobucdoverviewF2">Figure 2</a> may assist with the evaluation of a newborn with hyperammonemia.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figucdoverviewF2" co-legend-rid="figlgnducdoverviewF2"><a href="/books/NBK1217/figure/ucd-overview.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figucdoverviewF2" rid-ob="figobucdoverviewF2"><img class="small-thumb" src="/books/NBK1217/bin/ucd-overview-Image002.gif" src-large="/books/NBK1217/bin/ucd-overview-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgnducdoverviewF2"><h4 id="ucd-overview.F2"><a href="/books/NBK1217/figure/ucd-overview.F2/?report=objectonly" target="object" rid-ob="figobucdoverviewF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Steps in the evaluation of a newborn with hyperammonemia </p></div></div><p><b>Plasma ammonia concentration</b> elevation is usually the first identified laboratory abnormality in most of the urea cycle disorders. A plasma ammonia concentration of 150 &#x003bc;mol/L or higher associated with a normal anion gap and a normal plasma glucose concentration is a strong indication of a UCD [<a class="bk_pop" href="#ucd-overview.REF.summar.2001.s6">Summar &#x00026; Tuchman 2001</a>].</p><p><a class="figpopup" href="/books/NBK1217/figure/ucd-overview.F3/?report=objectonly" target="object" rid-figpopup="figucdoverviewF3" rid-ob="figobucdoverviewF3">Figure 3</a> highlights the use of the following recommended diagnostic tests to identify the specific urea cycle disorder.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figucdoverviewF3" co-legend-rid="figlgnducdoverviewF3"><a href="/books/NBK1217/figure/ucd-overview.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figucdoverviewF3" rid-ob="figobucdoverviewF3"><img class="small-thumb" src="/books/NBK1217/bin/ucd-overview-Image003.gif" src-large="/books/NBK1217/bin/ucd-overview-Image003.jpg" alt="Figure 3. " /></a><div class="icnblk_cntnt" id="figlgnducdoverviewF3"><h4 id="ucd-overview.F3"><a href="/books/NBK1217/figure/ucd-overview.F3/?report=objectonly" target="object" rid-ob="figobucdoverviewF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Testing used in the diagnosis of urea cycle disorders * If DNA testing is not informative, enzymatic testing is available for these disorders (see Evaluation Strategy).</p></div></div><p><b>Quantitative plasma amino acid analysis</b> can be used to arrive at a tentative diagnosis. (As the liver is not fully mature at birth, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> newborns often have plasma amino acid concentrations that are quite different from those in older children and adults.)</p><ul><li class="half_rhythm"><div><b>Plasma concentration of citrulline</b> helps discriminate between the proximal and distal urea cycle defects, as citrulline is the product of the proximal enzymes (CPS1, OTC, and NAGS) and a substrate for the distal enzymes (ASS1, ASL, ARG1).</div><ul><li class="half_rhythm"><div>Plasma citrulline is either absent or present only in trace amounts in neonatal-onset CPS1 deficiency, NAGS deficiency and OTC deficiency and present in low to low-normal concentrations in late-onset disease. Plasma citrulline is also reduced in ORNT1 deficiency.</div></li><li class="half_rhythm"><div>Marked elevation in plasma citrulline concentration is seen in ASS1 deficiency.</div></li><li class="half_rhythm"><div>Moderate elevation in plasma citrulline may be observed in citrin deficiency, along with an elevated threonine/serine ratio.</div></li><li class="half_rhythm"><div>A more moderate (~2- to 5-fold) increase in plasma citrulline concentration is seen in ASL deficiency, which is also associated with high levels of argininosuccinic acid (ASA) in plasma and urine. Note: ASA is absent in unaffected individuals[<a class="bk_pop" href="#ucd-overview.REF.summar.2001">Summar 2001</a>, <a class="bk_pop" href="#ucd-overview.REF.summar.2001.s6">Summar &#x00026; Tuchman 2001</a>].</div></li><li class="half_rhythm"><div>Plasma citrulline concentration is usually normal in ARG1 deficiency.</div></li></ul></li><li class="half_rhythm"><div><b>Plasma concentration of arginine</b> is markedly elevated in ARG1 deficiency. It may be reduced in all other urea cycle disorders; however, in partial UCD enzyme defects, it may be normal.</div></li><li class="half_rhythm"><div><b>Plasma concentration of ornithine</b> is elevated in ORNT1 deficiency, in which urine homocitrulline is also elevated. Ornithine is not elevated in OTC deficiency.</div></li></ul><p>Note: Plasma concentrations of glutamine, alanine, and asparagine, which serve as storage forms of waste nitrogen, are frequently elevated.</p><p><b>Urinary orotic acid</b> is measured to distinguish CPS1 deficiency or NAGS deficiency from OTC deficiency. It is normal or low in CPS1 deficiency and NAGS deficiency and significantly elevated in OTC deficiency. Note: Urinary orotic acid excretion can also be increased in argininemia (ARG1 deficiency) and citrullinemia type I (ASS1 deficiency).</p><p><b>Urine amino acid analysis</b> may be used to identify the presence of urine homocitrulline, observed in ORNT1 deficiency. Additionally, ASA concentrations are higher in urine than in plasma, and therefore urine amino acid profile may be helpful when small peaks of ASA or its anhydrides are difficult to resolve on plasma amino acid analysis.</p></div><div id="ucd-overview.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p>Molecular genetic testing is the primary method of diagnostic confirmation for all eight UCDs (see <a class="figpopup" href="/books/NBK1217/table/ucd-overview.T.urea_cycle_disorders_mole/?report=objectonly" target="object" rid-figpopup="figucdoverviewTureacycledisordersmole" rid-ob="figobucdoverviewTureacycledisordersmole">Table 3</a>). Molecular testing has supplanted measurement of enzyme activity as the definitive diagnostic test. However, enzymatic testing remains available for most disorders (see <a href="#ucd-overview.Enzyme_Activity">Enzyme Activity</a>), and may be helpful if DNA-based investigations are not informative.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> can be considered if the biochemical findings indicate that mutation of a particular gene is most likely.</div><div class="half_rhythm">Sequence analysis of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> of interest is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the case of OTC deficiency or only one or no pathogenic variant is found in the case of deficiencies of NAGS, CPS1, ASS1, ASL, ARG1, ORNT1, or citrin.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes the eight genes discussed in this <i>GeneReview</i> may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> varies by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="ucd-overview.T.urea_cycle_disorders_mole" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Urea Cycle Disorders: Molecular Genetics</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1217/table/ucd-overview.T.urea_cycle_disorders_mole/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ucd-overview.T.urea_cycle_disorders_mole_lrgtbl__"><table><thead><tr><th id="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disease Name</th><th id="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protein</th><th id="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Select OMIM Links</th></tr></thead><tbody><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carbamoylphosphate synthetase I deficiency</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CPS1</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carbamoyl-phosphate synthase</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/608307" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608307</a><br /><a href="http://omim.org/entry/237300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">237300</a></td></tr><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/otc-def/">Ornithine transcarbamylase deficiency</a></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>OTC</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ornithine carbamoyltransferase</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/300461" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300461</a><br /><a href="http://omim.org/entry/311250" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">311250</a></td></tr><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ASS1 deficiency (<a href="/books/n/gene/ctlm/">citrullinemia type I</a>)</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ASS1</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Argininosuccinate synthase</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/603470" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603470</a><br /><a href="http://omim.org/entry/215700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">215700</a></td></tr><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/args-aciduria/">ASL deficiency</a> (argininosuccinic aciduria)</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ASL</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Argininosuccinate lyase</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/608310" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608310</a><br /><a href="http://omim.org/entry/207900" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">207900</a></td></tr><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/arg1/">Arginase deficiency</a></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ARG1</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arginase-1</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/608313" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608313</a><br /><a href="http://omim.org/entry/207800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">207800</a></td></tr><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NAGS deficiency</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NAGS</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N-acetylglutamate synthase</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/608300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608300</a><br /><a href="http://omim.org/entry/237310" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">237310</a></td></tr><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hhhs/">Ornithine translocase (ORNT1) deficiency</a></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC25A15</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ornithine Transporter (ORNT1)</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://www.omim.org/entry/603861" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603861</a><br /><a href="http://www.omim.org/entry/238970" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">238970</a></td></tr><tr><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/citrin/">Citrin deficiency</a></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC25A13</i></td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Citrin</td><td headers="hd_h_ucd-overview.T.urea_cycle_disorders_mole_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://www.omim.org/entry/603859" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603859</a><br /><a href="http://www.omim.org/entry/605814" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605814</a><br /><a href="http://www.omim.org/entry/603471" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603471</a></td></tr></tbody></table></div></div></div><div id="ucd-overview.Enzyme_Activity"><h3>Enzyme Activity</h3><p>If molecular testing is uninformative, the following disorders can be diagnosed by assay of enzyme activity:</p><ul><li class="half_rhythm"><div>CPS1 deficiency, NAGS deficiency, or OTC deficiency: hepatocytes</div></li><li class="half_rhythm"><div>ASL deficiency, ASS1 deficiency or ORNT1 deficiency: fibroblasts</div></li><li class="half_rhythm"><div>ARG1 deficiency: erythrocytes</div></li></ul></div><div id="ucd-overview.Newborn_Screening"><h3>Newborn Screening</h3><p>Current <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> panels in the United States using tandem mass spectrometry detect abnormal concentrations of analytes associated with ASS1 deficiency, and ASL deficiency in all states; however, the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity of screening for these disorders varies by state.</p><p>Other disorders are screened for in some states only (see <a href="http://data.newsteps.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">data.newsteps.org</a> for information on disorders screened for by state). For example:</p><ul><li class="half_rhythm"><div>CPS1 deficiency is screened for in Florida, Maine, Massachusetts, Mississippi, New Hampshire, Pennsylvania, Rhode Island, and Vermont.</div></li><li class="half_rhythm"><div>OTC deficiency is screened for in Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont, and is likely to be detected in Kentucky and Utah.</div></li><li class="half_rhythm"><div>Arginase deficiency is screened for in 35 states and likely to be detected in four more.</div></li><li class="half_rhythm"><div>Citrin deficiency is screened for in 36 states and likely to be detected in 13 more.</div></li></ul><p><b>IMPORTANT NOTE:</b> The <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity of screening for these disorders varies by state, and current newborn metabolic screen cannot reliably identify all cases of these disorders. Additionally, even for UCDs detectable by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>, neonates are often symptomatic prior to availability of the screening results; thus a high level of clinical suspicion on the part of health care providers is necessary.</p></div></div><div id="ucd-overview.Differential_Diagnosis_of_U"><h2 id="_ucd-overview_Differential_Diagnosis_of_U_">Differential Diagnosis of Urea Cycle Disorders</h2><p>A number of other disorders that perturb the liver can result in hyperammonemia and mimic the effects of a urea cycle disorder. These include diseases of the liver and biliary tract, use of certain medications, and a number of other genetic disorders (see <a class="figpopup" href="/books/NBK1217/table/ucd-overview.T.genetic_disorders_to_cons/?report=objectonly" target="object" rid-figpopup="figucdoverviewTgeneticdisorderstocons" rid-ob="figobucdoverviewTgeneticdisorderstocons">Table 4</a>).</p><p><b>Diseases of the liver and biliary tract</b></p><ul><li class="half_rhythm"><div>Herpes simplex virus infection</div></li><li class="half_rhythm"><div>Vascular bypass of the liver</div></li><li class="half_rhythm"><div>Biliary atresia</div></li><li class="half_rhythm"><div>Acute liver failure</div></li></ul><p><b>Medications</b></p><ul><li class="half_rhythm"><div>Valproic acid</div></li><li class="half_rhythm"><div>Cyclophosphamide</div></li><li class="half_rhythm"><div>5-pentanoic acid</div></li></ul><div id="ucd-overview.T.genetic_disorders_to_cons" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Genetic Disorders to Consider in the Differential Diagnosis of a Urea Cycle Disorder</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1217/table/ucd-overview.T.genetic_disorders_to_cons/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ucd-overview.T.genetic_disorders_to_cons_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4" id="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/UCD</th><th headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4" id="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from UCD</th></tr></thead><tbody><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/propionic-a/">Propionic acidemia</a></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PCCA, PCCB</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Metabolic acidosis, hyperglycinemia, diagnostic organic acids, cylcarnitine profile</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mma/">Isolated methylmalonic acidemia</a></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MUT, MMAA, MMAB</i>, and others</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Metabolic acidosis, diagnostic organic acids, acylcarnitine profile</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Isovaleric acidemia<br />(OMIM <a href="http://omim.org/entry/243500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">243500</a>)</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>IVD</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Metabolic acidosis (possibly), diagnostic organic acids, acylcarnitine profile</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ca5a-def/">Carbonic anhydrase VA deficiency</a></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CA5A</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; lactate or abnormal urine organic acids</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/lpi/">Lysinuric protein intolerance</a></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC7A7</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; lysine, ornithine, arginine in the urine</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fatty acid oxidation disorders (see <a href="/books/n/gene/scad/">SCAD</a>, <a href="/books/n/gene/mcad/">MCAD</a>, <a href="/books/n/gene/vlcad/">VLCAD</a>)</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver dysfunction</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; diagnostic acylcarnitines</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperinsulinism-hyperammonemia syndrome (see <a href="/books/n/gene/hi/">Familial Hyperinsulinism</a>)</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GLUD1</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypoglycemia, hyperinsulinism</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OAT deficiency (in neonates)<br />(OMIM <a href="http://omim.org/entry/258870" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">258870</a>)</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>OAT</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ornithine may be &#x02193; in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> neonates who present w/hyperammonemia. However, older patients w/OAT deficiency have markedly &#x02191; levels of ornithine &#x00026; do not present w/hyperammonemia.</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/tyrosinemia/">Tyrosinemia type I</a></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FAH</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver dysfunction</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diagnostic amino acids, succinylacetone</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/galactosemia/">Classic galactosemia</a></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GALT</i></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver dysfunction</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; galactose-1-phosphate, &#x02193; galactose-1-phosphate uridyltransferase enzyme activity</td></tr><tr><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mt-overview/">Mitochondrial disorders</a></td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR, mt, XL</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver dysfunction, &#x02193; citrulline (occasionally)</td><td headers="hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_1_4 hd_h_ucd-overview.T.genetic_disorders_to_cons_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma amino acids w/&#x02191; alanine, plasma lactate elevation</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MCAD = medium-chain acyl-coenzyme A dehydrogenase deficiency; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; mt = mitochondrial; OAT = ornithine aminotransferase; SCAD = short-chain acyl-coenzyme A dehydrogenase deficiency; VLCAD = very long-chain acyl-coenzyme A dehydrogenase deficiency; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd></dl></div></div></div></div><div id="ucd-overview.Genetic_Risk_Assessment_in"><h2 id="_ucd-overview_Genetic_Risk_Assessment_in_">Genetic Risk Assessment in Family Members</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ucd-overview.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>OTC deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p><p>The rest of the urea cycle disorders (deficiencies of NAGS, CPS1, ASS1, ASL, ARG1, ORNT1, and citrin) are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="ucd-overview.Risk_to_Family_Members__XLi"><h3>Risk to Family Members &#x02013; X-Linked Inheritance</h3><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Note: If a woman has more than one affected child and no other affected relatives and if the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Germline mosaicism has been reported in OTC deficiency [<a class="bk_pop" href="#ucd-overview.REF.bowling.1999.452">Bowling et al 1999</a>]; however, because the frequency is not known the general <a class="def" href="/books/n/gene/glossary/def-item/background-risk/">background risk</a> for germline mosaicism &#x02013; 3%-4% &#x02013; should be used.</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a carrier. About 26% of affected males had a <i>de novo</i> pathogenic variant in one study [<a class="bk_pop" href="#ucd-overview.REF.r_egger.2014.21">R&#x000fc;egger et al 2014</a>].</div></li></ul><p><b>Parents of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>A female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have inherited the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from either her mother or her father, or the pathogenic variant may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>.</div></li><li class="half_rhythm"><div>Detailed evaluation of the parents and review of the extended family history may help distinguish probands with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from those with an inherited pathogenic variant. Molecular genetic testing of the mother (and possibly the father) can determine if the pathogenic variant was inherited.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%.</div><ul><li class="half_rhythm"><div>Males who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>Females who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may or may not develop clinical findings related to the disorder.</div></li></ul></li><li class="half_rhythm"><div>If the father of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, all of the proband's female sibs and none of the male sibs will inherit the pathogenic variant.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low, but greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>For additional specific <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> considerations</b> see <a href="/books/n/gene/otc-def/">OTC Deficiency</a>: Heterozygous Females, Evaluation of Relatives at Risk, and Risk to Family Members.</p></div><div id="ucd-overview.Risk_to_Family_Members__Aut"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (carriers) for one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Carrier (<a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>) detection.</b> Carrier testing for at-risk relatives requires prior identification of the urea cycle disorder-related pathogenic variants in the family.</p></div></div><div id="ucd-overview.Acute_Management_of_a_Urea"><h2 id="_ucd-overview_Acute_Management_of_a_Urea_">Acute Management of a Urea Cycle Disorder</h2><p>The extent of disease in an individual diagnosed with a urea cycle disorder can be estimated by the rapidity of onset of neurologic symptoms, the degree to which the brain is involved, and to a lesser extent the plasma ammonia concentration.</p><p>The NIH-funded <a href="http://www.rarediseasesnetwork.org/cms/UCDC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Urea Cycle Disorders Consortium</a> provides expert diagnosis and treatment of urea cycle disorders as well as clinical and therapeutic studies.</p><p>Once a diagnosis of a UCD is made, treatment of acute manifestations can be started.</p><p><b>Subsequent treatment</b> should be tailored to the specific urea cycle disorder. See:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/otc-def/">Ornithine Transcarbamylase Deficiency</a> (OTC deficiency);</div></li><li class="half_rhythm"><div><a href="/books/n/gene/ctlm/">Citrullinemia Type I</a> (ASS1 deficiency);</div></li><li class="half_rhythm"><div><a href="/books/n/gene/args-aciduria/">Argininosuccinic Aciduria</a> (ASL deficiency);</div></li><li class="half_rhythm"><div><a href="/books/n/gene/arg1/">Arginase Deficiency</a> (hyperargininemia, ARG1 deficiency);</div></li><li class="half_rhythm"><div><a href="/books/n/gene/hhhs/">Ornithine Translocase Deficiency</a> (ORNT1 deficiency, hyperornithinemia-hyperammonemia-homocitrullinuria syndrome);</div></li><li class="half_rhythm"><div><a href="/books/n/gene/citrin/">Citrin Deficiency</a>.</div></li></ul><p>For NAGS deficiency see <a class="bk_pop" href="#ucd-overview.REF.ah_mew.2011.127">Ah Mew &#x00026; Caldovic [2011]</a>.</p><p>Chronic management of CPS1 deficiency is similar to that of OTC deficiency; however, some patients with CPS1 deficiency may also benefit from therapy with oral N-carbamylglutamate [<a class="bk_pop" href="#ucd-overview.REF.diezfernandez.2013.1149">Diez-Fernandez et al 2013</a>, <a class="bk_pop" href="#ucd-overview.REF.ah_mew.2014.401">Ah Mew et al 2014</a>].</p><div id="ucd-overview.Treatment_of_Acute_Manifest"><h3>Treatment of Acute Manifestations</h3><p>Care of an individual with a urea cycle disorder should be provided by a team coordinated by a metabolic specialist in a tertiary care center.</p><p>In the acute phase, the mainstays of treatment are the following:</p><p><b>Rapidly return plasma ammonia concentrations to normal physiologic levels.</b> This is necessary even without a definitive diagnosis, given the toxic effect of elevated plasma ammonia concentration. The best way to reduce plasma ammonia concentration quickly is by dialysis. The faster the flow rate, the faster the clearance. The method employed depends on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's circumstances and available resources. In general, the best choice for an individual patient is whatever method the local treating team is most comfortable with and can implement most quickly. The various renal replacement modalities are reviewed by <a class="bk_pop" href="#ucd-overview.REF.gupta.2016.1872">Gupta et al [2016]</a>.</p><ul><li class="half_rhythm"><div>The fastest method is use of pump-driven dialysis, in which an extra corporeal membrane oxygenation (ECMO) pump is used to drive a hemodialysis machine.</div></li><li class="half_rhythm"><div>Intermittent hemofiltration (both arteriovenous and venovenous) and hemodialysis are more likely to be available than ECMO-driven dialysis.</div></li><li class="half_rhythm"><div>Continuous renal replacement therapies have lower clearance than intermittent dialysis, but are less prone to interruption and may be better tolerated in sick neonates.</div></li><li class="half_rhythm"><div>Clearance with peritoneal dialysis is substantially lower than with hemodialysis; therefore, hemodialysis (if available) is typically preferred. However, published outcome data are limited.</div></li><li class="half_rhythm"><div>Intermittent dialysis can usually be discontinued when plasma ammonia concentration falls below 150 &#x000b5;mol/L, but may vary based on clinical evaluation by a clinician experienced in the treatment of metabolic disease. Affected individuals often experience a "rebound" hyperammonemia that may require further dialysis. This may be attenuated with the use of continuous renal replacement therapies following intermittent HD [<a class="bk_pop" href="#ucd-overview.REF.gupta.2016.1872">Gupta et al 2016</a>].</div></li></ul><p><b>Perform pharmacologic interventions to allow alternative pathway excretion of excessive nitrogen</b> (see <a class="figpopup" href="/books/NBK1217/table/ucd-overview.T.iv_ammonia_scavenger_ther/?report=objectonly" target="object" rid-figpopup="figucdoverviewTivammoniascavengerther" rid-ob="figobucdoverviewTivammoniascavengerther">Table 5</a>).</p><ul><li class="half_rhythm"><div class="half_rhythm">Nitrogen scavenger therapy (sodium phenylacetate and sodium benzoate) is available as an intravenous infusion for acute management and an oral preparation for long-term maintenance.</div></li><li class="half_rhythm"><div class="half_rhythm">Deficient urea cycle intermediates need to be replaced depending on the diagnosis; these can include arginine (IV infusion) and/or citrulline (oral preparation).</div><div class="half_rhythm">Note: Continuous arginine hydrochloride (HCl) infusion requires central access, as extravasion from a peripheral IV has on multiple occasions resulted in severe cutaneous necrosis.</div></li><li class="half_rhythm"><div class="half_rhythm">Sodium phenylacetate and sodium benzoate can be infused through a peripheral IV; however, central access is preferred.</div></li><li class="half_rhythm"><div class="half_rhythm">In persons with NAGS deficiency and in some with CPS1 deficiency, replacement of n-acetylglutamate with the analog molecule carbamyl glutamate (Carbaglu<sup>&#x000ae;</sup>) can improve the clinical symptoms or in NAGS deficiency can be almost curative. This compound is available in the US and should be added to the treatment regimen in a patient without a clear diagnosis at initial presentation. Dosing in adults and children is 100 mg/kg/day to 250 mg/kg/day divided into two to four doses. The only form currently available is an oral preparation; thus, administration of the medication by nasogastric/jejunal tube is necessary in the treatment of acute manifestations.</div></li></ul><div id="ucd-overview.T.iv_ammonia_scavenger_ther" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>IV Ammonia Scavenger Therapy Protocol</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1217/table/ucd-overview.T.iv_ammonia_scavenger_ther/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ucd-overview.T.iv_ammonia_scavenger_ther_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_1" style="text-align:left;vertical-align:middle;">Deficiency</th><th id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_2" style="text-align:left;vertical-align:middle;">Patient Weight</th><th id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Components of Infusion Solution</th><th id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Dosage Provided</th><th id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_5" rowspan="2" scope="col" colspan="1" headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_5" style="text-align:left;vertical-align:middle;">Administration</th></tr><tr><th headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3" id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sodium phenylacetate&#x00026; sodium benzoate&#x000a0;<sup>1,&#x000a0;2</sup></th><th headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3" id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arginine HCl injection, 10%&#x000a0;<sup>2</sup></th><th headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4" id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sodium phenyl-acetate</th><th headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4" id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sodium benzoate</th><th headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4" id="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arginine HCl</th></tr></thead><tbody><tr><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>CPS &#x00026; OTC</b></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><b>0-20 kg</b></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.5 mL/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.0 mL/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250 mg/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250 mg/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">200 mg/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_5" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Loading&#x000a0;<sup>3</sup><br />Maintenance&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>ASS1 &#x00026; ASL</b></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">2.5 mL/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.0 mL/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250 mg/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250 mg/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">600 mg/kg</td></tr><tr><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>CPS &#x00026; OTC</b></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><b>&#x0003e;20 kg</b></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">55 mL/m<sup>2</sup></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.0 mL/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.5 g/m<sup>2</sup></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.5 g/m<sup>2</sup></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4000 mg/m<sup>2</sup></td></tr><tr><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>ASS1 &#x00026; ASL</b></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">55 mL/m<sup>2</sup></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_3 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.0 mL/kg</td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.5 g/m<sup>2</sup></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.5 g/m<sup>2</sup></td><td headers="hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_1_4 hd_h_ucd-overview.T.iv_ammonia_scavenger_ther_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12000 mg/m<sup>2</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ucd-overview.TF.5.1"><p class="no_margin">Sodium phenylacetate/sodium benzoate must be diluted with sterile dextrose injection 10% before administration.</p></div></dd><dt>2. </dt><dd><div id="ucd-overview.TF.5.2"><p class="no_margin">Before dilution</p></div></dd><dt>3. </dt><dd><div id="ucd-overview.TF.5.3"><p class="no_margin">&#x0003e;90-120 minutes</p></div></dd><dt>4. </dt><dd><div id="ucd-overview.TF.5.4"><p class="no_margin">&#x0003e;24 hours; arginine infusion not to exceed 150 mg/kg/h</p></div></dd></dl></div></div></div><p><b>Treat catabolic state with calories from glucose, fats, and essential amino acids.</b> The introduction of nutrition support in the following manner is necessary for patients on dialysis or hemofiltration in order to resolve the catabolic state while avoiding overuse of enteral feeds.</p><ul><li class="half_rhythm"><div>Complete restriction of protein should not exceed 12-24 hours because depletion of essential amino acids results in protein catabolism and nitrogen release. Frequent (often daily) quantitative assessments of plasma amino acid concentrations can help optimize nutritional management by allowing the clinician to maintain adequate levels of essential amino acids without having to provide excess nitrogen. Maintenance of appropriate levels of essential amino acids is necessary to reverse the typical catabolic state because most acutely ill patients either present with essential amino acid deficiency or become deficient quickly.</div></li><li class="half_rhythm"><div>Enteral nutrition is preferred; however, intravenous (total parenteral nutrition) is an option if the patient is so clinically unstable that adequate enteral intake is impossible. Intolerance of enteral feeding should not lead to further depletion of essential amino acids.</div></li><li class="half_rhythm"><div>The placement of a nasogastric/jejunal tube at admission is warranted for slow drip administration of solutions of essential amino acids and infant formulas and administration of cofactors like carbamyl glutamate (analog of n-acetylglutamate).</div></li><li class="half_rhythm"><div>Multiple other strategies to combat catabolism can be used, including low-dose continuous infusion of insulin with maintenance of adequate glucose delivery by high continuous delivery of carbohydrate-containing fluids; however, caution is advised since patients are often exquisitely sensitive to either the glucose or insulin.</div></li></ul><p><b>Reduce the risk for neurologic damage</b></p><ul><li class="half_rhythm"><div>Use intravenous fluids (&#x02265;10% dextrose with appropriate electrolytes) for physiologic stabilization.</div></li><li class="half_rhythm"><div>Use cardiac pressors as necessary while avoiding overhydration.</div></li><li class="half_rhythm"><div>Consider the use of continuous bedside EEG to detect subclinical seizures. Patients in deep coma may have subclinical seizures that are non-convulsive and therefore not apparent.</div></li></ul><p>Note: In patients with prolonged hyperammonemic coma and evidence of severe neurologic damage, the relative risks versus benefits of all the treatments discussed above should be considered on an individual basis.</p></div></div><div id="ucd-overview.References"><h2 id="_ucd-overview_References_">References</h2><div id="ucd-overview.Published_Guidelines__Conse"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.alfadhel.2016">Alfadhel M, Mutairi FA, Makhseed N, Jasmi FA, Al-Thihli K, Al-Jishi E, AlSayed M, Al-Hassnan ZN, Al-Murshedi F, H&#x000e4;berle J, Ben-Omran T. Guidelines for acute management of hyperammonemia in the Middle East region. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820220/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2016. Accessed 11-1-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.h_berle.2012">H&#x000e4;berle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Lindner M, Rubio V, Dionisi-Vici C. Suggested guidelines for the diagnosis and management of urea cycle disorders. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488504/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 11-1-18. [<a href="/pmc/articles/PMC3488504/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3488504</span></a>] [<a href="/pubmed/22642880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22642880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.summar.2001">Summar M. Current strategies for the management of neonatal urea cycle disorders. Available <a href="https://www.rarediseasesnetwork.org/cms/Portals/UCDC/Docs/Newborn-Hyperammonemia-2001.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2001. Accessed 11-1-18. [<a href="/pubmed/11148547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF4">Urea Cycle Disorders Conference Group. Consensus Statement from a Conference for the Management of Urea Cycle Disorders. J Pediatr. Available <a href="http://www.nucdf.org/documents/Consensus%20Documents/Statement.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2001. Accessed 11-1-18.</div></li></ul></div><div id="ucd-overview.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.ah_mew.2011.127">Ah Mew N, Caldovic L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. <span><span class="ref-journal">Appl Clin Genet. </span>2011;<span class="ref-vol">4</span>:127–35.</span> [<a href="/pmc/articles/PMC3681184/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3681184</span></a>] [<a href="/pubmed/23776373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23776373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.ah_mew.2013.324">Ah Mew N, Krivitzky L, McCarter R, Batshaw M, Tuchman M, et al.  Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. <span><span class="ref-journal">J Pediatr. </span>2013;<span class="ref-vol">162</span>:324–9.e1.</span> [<a href="/pmc/articles/PMC4440324/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4440324</span></a>] [<a href="/pubmed/22901741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22901741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.ah_mew.2014.401">Ah Mew N, McCarter R, Daikhin Y, Lichter-Konecki U, Nissim I, Yudkoff M, Tuchman M. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. <span><span class="ref-journal">J Pediatr. </span>2014;<span class="ref-vol">165</span>:401–3.</span> [<a href="/pmc/articles/PMC4111993/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4111993</span></a>] [<a href="/pubmed/24880889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24880889</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.albrecht.2010.1303">Albrecht J, Zieli&#x00144;ska M, Norenberg MD. Glutamine as a mediator of ammonia neurotoxicity: A critical appraisal. <span><span class="ref-journal">Biochem Pharmacol. </span>2010;<span class="ref-vol">80</span>:1303–8.</span> [<a href="/pmc/articles/PMC4714775/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4714775</span></a>] [<a href="/pubmed/20654582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20654582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.braissant.2013.595">Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013;<span class="ref-vol">36</span>:595–612.</span> [<a href="/pubmed/23109059" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23109059</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.bowling.1999.452">Bowling F, McGown I, McGill J, Cowley D, Tuchman M. Maternal gonadal mosaicism causing ornithine transcarbamylase deficiency. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">85</span>:452–4.</span> [<a href="/pubmed/10405441" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10405441</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.brusilow.1995.293">Brusilow SW. Urea cycle disorders: clinical paradigm of hyperammonemic encephalopathy. <span><span class="ref-journal">Prog Liver Dis. </span>1995;<span class="ref-vol">13</span>:293–309.</span> [<a href="/pubmed/9224507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9224507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.caldovic.2003.364">Caldovic L, Morizono H, Panglao MG, Cheng SF, Packman S, Tuchman M. Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia. <span><span class="ref-journal">Hum Genet. </span>2003;<span class="ref-vol">112</span>:364–8.</span> [<a href="/pubmed/12594532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12594532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.cederbaum.2004.s38">Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap? <span><span class="ref-journal">Mol Genet Metab. </span>2004;<span class="ref-vol">81</span>:S38–44.</span> [<a href="/pubmed/15050972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15050972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.diezfernandez.2013.1149">Diez-Fernandez C, Mart&#x000ed;nez AI, Pekkala S, Barcelona B, P&#x000e9;rez-Arellano I, Guadalajara AM, Summar M, Cervera J, Rubio V. Molecular characterization of carbamoyl-phosphate synthetase (CPS1) deficiency using human recombinant CPS1 as a key tool. <span><span class="ref-journal">Hum Mutat. </span>2013;<span class="ref-vol">34</span>:1149–59.</span> [<a href="/pubmed/23649895" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23649895</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.enns.2007.2282">Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">356</span>:2282–92.</span> [<a href="/pubmed/17538087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17538087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.gardeitchik.2012.328">Gardeitchik T, Humphrey M, Nation J, Boneh A. Early clinical manifestations and eating patterns in patients with urea cycle disorders. <span><span class="ref-journal">J Pediatr. </span>2012;<span class="ref-vol">161</span>:328–32.</span> [<a href="/pubmed/22424941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22424941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.gropman.2007.865">Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. <span><span class="ref-journal">J Inherit Metab Dis. </span>2007;<span class="ref-vol">30</span>:865–79.</span> [<a href="/pmc/articles/PMC3758693/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3758693</span></a>] [<a href="/pubmed/18038189" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18038189</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.gupta.2016.1872">Gupta S, Fenves AZ, Hootkins R. The Role of RRT in Hyperammonemic Patients. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2016;<span class="ref-vol">11</span>:1872–8.</span> [<a href="/pmc/articles/PMC5053785/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5053785</span></a>] [<a href="/pubmed/27197910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27197910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.jainghai.2011.107">Jain-Ghai S, Nagamani SC, Blaser S, Siriwardena K, Feigenbaum A. Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported? <span><span class="ref-journal">Mol Genet Metab. </span>2011;<span class="ref-vol">104</span>:107–11.</span> [<a href="/pmc/articles/PMC3171515/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3171515</span></a>] [<a href="/pubmed/21802329" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21802329</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.kobayashi.2006.1047">Kobayashi K, Iijima M, Ushikai M, Ikeda S, Saheki T. Citrin deficiency. <span><span class="ref-journal">J Jpn Pediatr Soc. </span>2006;<span class="ref-vol">110</span>:1047–59.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.k_lker.2015.1041">K&#x000f6;lker S, Garcia-Cazorla A, Valayannopoulos V, Lund AM, Burlina AB, Sykut-Cegielska J, Wijburg FA, Teles EL, Zeman J, Dionisi-Vici C, Bari&#x00107; I, Karall D, Augoustides-Savvopoulou P, Aksglaede L, Arnoux JB, Avram P, Baumgartner MR, Blasco-Alonso J, Chabrol B, Chakrapani A, Chapman K. I Saladelafont EC, Couce ML, de Meirleir L, Dobbelaere D, Dvorakova V, Furlan F, Gleich F, Gradowska W, Gr&#x000fc;newald S, Jalan A, H&#x000e4;berle J, Haege G, Lachmann R, Laemmle A, Langereis E, de Lonlay P, Martinelli D, Matsumoto S, M&#x000fc;hlhausen C, de Baulny HO, Ortez C, Pe&#x000f1;a-Quintana L, Ramad&#x0017e;a DP, Rodrigues E, Scholl-B&#x000fc;rgi S, Sokal E, Staufner C, Summar ML, Thompson N, Vara R, Pinera IV, Walter JH, Williams M, Burgard P. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. <span><span class="ref-journal">J Inherit Metab Dis. </span>2015;<span class="ref-vol">38</span>:1041–57.</span> [<a href="/pubmed/25875215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25875215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.krebs.1932.325">Krebs HA, Henseleit K. Untersuchungen uber die harnstoffbildung im tierkorper. <span><span class="ref-journal">Hoppe-Seyler's Z Physiol Chem. </span>1932;<span class="ref-vol">210</span>:325–32.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.krivitzky.2009.96">Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. <span><span class="ref-journal">Pediatr Res. </span>2009;<span class="ref-vol">66</span>:96–101.</span> [<a href="/pmc/articles/PMC2746951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2746951</span></a>] [<a href="/pubmed/19287347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19287347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.lee.2011.983">Lee HC, Mak CM, Lam CW, Yuen YP, Chan AO, Shek CC, Siu TS, Lai CK, Ching CK, Siu WK, Chen SP, Law CY, Tai HL, Tam S, Chan AY. Analysis of inborn errors of metabolism: disease spectrum for expanded newborn screening in Hong Kong. <span><span class="ref-journal">Chin Med J (Engl). </span>2011;<span class="ref-vol">124</span>:983–9.</span> [<a href="/pubmed/21542954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21542954</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.lichterkonecki.2008.492">Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonemic brain: Shedding new light on the pathophysiology of the brain damage in hyperammonemia. <span><span class="ref-journal">J Inherit Metab Dis. </span>2008;<span class="ref-vol">31</span>:492–502.</span> [<a href="/pubmed/18683079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18683079</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.lichterkonecki.2008.365">Lichter-Konecki U, Mangin JM, Gordish-Dressman H, Hoffman EP, Gallo V. Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo. <span><span class="ref-journal">Glia. </span>2008;<span class="ref-vol">56</span>:365–77.</span> [<a href="/pmc/articles/PMC4116685/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4116685</span></a>] [<a href="/pubmed/18186079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18186079</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.lu.2005.338">Lu YB, Kobayashi K, Ushikai M, Tabata A, Iijima M, Li MX, Lei L, Kawabe K, Taura S, Yang Y, Liu TT, Chiang SH, Hsiao KJ, Lau YL, Tsui LC, Lee DH, Saheki T. Frequency and distribution in East Asia of 12 mutations identified in the SLC25A13 gene of Japanese patients with citrin deficiency. <span><span class="ref-journal">J Hum Genet. </span>2005;<span class="ref-vol">50</span>:338–46.</span> [<a href="/pubmed/16059747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16059747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.nagamani.2012.836">Nagamani SC, Campeau PM, Shchelochkov OA, Premkumar MH, Guse K, Brunetti-Pierri N, Chen Y, Sun Q, Tang Y, Palmer D, Reddy AK, Li L, Slesnick TC, Feig DI, Caudle S, Harrison D, Salviati L, Marini JC, Bryan NS, Erez A, Lee B. Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. <span><span class="ref-journal">Am J Hum Genet. </span>2012;<span class="ref-vol">90</span>:836–46.</span> [<a href="/pmc/articles/PMC3376491/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3376491</span></a>] [<a href="/pubmed/22541557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22541557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.pearson.2001.1832">Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, Scott N, Summar ML. Neonatal pulmonary hypertension--urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. <span><span class="ref-journal">N Engl J Med. </span>2001;<span class="ref-vol">344</span>:1832–8.</span> [<a href="/pubmed/11407344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11407344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.r_egger.2014.21">R&#x000fc;egger CM, Lindner M, Ballhausen D, Baumgartner MR, Beblo S, Das A, Gautschi M, Glahn EM, Gr&#x000fc;nert SC, Hennermann J, Hochuli M, Huemer M, Karall D, K&#x000f6;lker S, Lachmann RH, Lotz-Havla A, M&#x000f6;slinger D, Nuoffer JM, Plecko B, Rutsch F, Santer R, Spiekerkoetter U, Staufner C, Stricker T, Wijburg FA, Williams M, Burgard P, H&#x000e4;berle J. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014;<span class="ref-vol">37</span>:21–30.</span> [<a href="/pmc/articles/PMC3889631/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3889631</span></a>] [<a href="/pubmed/23780642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23780642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.sprouse.2014.136">Sprouse C, King J, Helman G, Pacheco-Col&#x000f3;n I, Shattuck K, Breeden A, Seltzer R, VanMeter JW, Gropman AL. Investigating neurological deficits in carriers and affected patients with ornithine transcarbamylase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">113</span>:136–41.</span> [<a href="/pmc/articles/PMC4458385/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4458385</span></a>] [<a href="/pubmed/24881970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24881970</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.summar.2001.s30">Summar M. Current strategies for the management of neonatal urea cycle disorders. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:S30–9.</span> [<a href="/pubmed/11148547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.summar.2001.s6">Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:S6–10.</span> [<a href="/pubmed/11148544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.summar.2008.1420">Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. <span><span class="ref-journal">Acta Paediatr. </span>2008;<span class="ref-vol">97</span>:1420–5.</span> [<a href="/pmc/articles/PMC2675643/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2675643</span></a>] [<a href="/pubmed/18647279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18647279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.summar.2013.179">Summar ML, Koelker S, Freedenberg D, Le Mons C, Ha J, Lee HS, Kirmse B., European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD).  The incidence of urea cycle disorders. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">110</span>:179–80.</span> [<a href="/pmc/articles/PMC4364413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4364413</span></a>] [<a href="/pubmed/23972786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23972786</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.tabata.2008.534">Tabata A, Sheng J-S, Ushikai M, Song Y-Z, Gao H-Z, Lu Y-B, Okumura F, Iijima M, Mutoh K, Kishida S, Saheki T, Kobayashi K. Identification of 13 novel mutations including a retrotransposal insertion in SLC25A13 gene and frequency of 30 mutations found in patients with citrin deficiency. <span><span class="ref-journal">J Hum Genet. </span>2008;<span class="ref-vol">53</span>:534–45.</span> [<a href="/pubmed/18392553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18392553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ucd-overview.REF.tuchman.2008.397">Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, McCarter RJ, Krischer JP, Batshaw ML. Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network; Cross-sectional multicenter study of patients with urea cycle disorders in the United States. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">94</span>:397–402.</span> [<a href="/pmc/articles/PMC2640937/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2640937</span></a>] [<a href="/pubmed/18562231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18562231</span></a>]</div></li></ul></div></div><div id="ucd-overview.Chapter_Notes"><h2 id="_ucd-overview_Chapter_Notes_">Chapter Notes</h2><div id="ucd-overview.Author_History"><h3>Author History</h3><p>Nicholas Ah Mew, MD (2014-present)<br />Kimberly A Chapman, MD, PhD (2011-present)<br />Andrea Gropman, MD (2011-present)<br />Brendan C Lanpher, MD (2011-present)<br />Uta Lichter-Konecki, MD, PhD; Columbia University (2011-2014)<br />Kara L Simpson, MS, CGC (2014-present)<br />Marshall L Summar, MD (2003-present)<br />Mendel Tuchman, MD; Children's National Medical Center (2003-2005)</p></div><div id="ucd-overview.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>22 June 2017 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 April 2015 (nam) Revision: additions to pharmocologic interventions and differential diagnosis</div></li><li class="half_rhythm"><div>11 September 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 September 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 August 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 June 2004 (mls) Revision: testing</div></li><li class="half_rhythm"><div>29 April 2003 (me) Overview posted live</div></li><li class="half_rhythm"><div>29 January 2001 (mls) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1217</span><span class="label">PMID: <a href="/pubmed/20301396" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301396</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/epm1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/urofacial/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1217&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1217/?report=reader">PubReader</a></li><li><a href="/books/NBK1217/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1217" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1217" style="display:none" title="Cite this Page"><div class="bk_tt">Ah Mew N, Simpson KL, Gropman AL, et al. Urea Cycle Disorders Overview. 2003 Apr 29 [Updated 2017 Jun 22]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1217/pdf/Bookshelf_NBK1217.pdf">PDF version of this page</a> (668K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ucd-overview.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ucd-overview.Definition_of_the_Urea_Cycl" ref="log$=inpage&amp;link_id=inpage">Definition of the Urea Cycle and Clinical Characteristics of Urea Cycle Disorders</a></li><li><a href="#ucd-overview.Causes_of_Urea_Cycle_Disord" ref="log$=inpage&amp;link_id=inpage">Causes of Urea Cycle Disorders (UCDs) and Prevalence</a></li><li><a href="#ucd-overview.Evaluation_Strategy_to_Iden" ref="log$=inpage&amp;link_id=inpage">Evaluation Strategy to Identify the Specific Type and Genetic Cause of a Urea Cycle Disorder in a Proband</a></li><li><a href="#ucd-overview.Differential_Diagnosis_of_U" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis of Urea Cycle Disorders</a></li><li><a href="#ucd-overview.Genetic_Risk_Assessment_in" ref="log$=inpage&amp;link_id=inpage">Genetic Risk Assessment in Family Members</a></li><li><a href="#ucd-overview.Acute_Management_of_a_Urea" ref="log$=inpage&amp;link_id=inpage">Acute Management of a Urea Cycle Disorder</a></li><li><a href="#ucd-overview.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ucd-overview.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=445[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ASS1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1373[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CPS1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5009[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">OTC</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=383[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ARG1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=162417[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NAGS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=435[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ASL</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1500150" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1500150" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18666241" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Genetic variation in the urea cycle: a model resource for investigating key candidate genes for common diseases.</a><span class="source">[Hum Mutat. 2009]</span><div class="brieflinkpop offscreen_noflow">Genetic variation in the urea cycle: a model resource for investigating key candidate genes for common diseases.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mitchell S, Ellingson C, Coyne T, Hall L, Neill M, Christian N, Higham C, Dobrowolski SF, Tuchman M, Summar M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Mutat. 2009 Jan; 30(1):56-60. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24945279" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Aberrant expression and distribution of enzymes of the urea cycle and other ammonia metabolizing pathways in dogs with congenital portosystemic shunts.</a><span class="source">[PLoS One. 2014]</span><div class="brieflinkpop offscreen_noflow">Aberrant expression and distribution of enzymes of the urea cycle and other ammonia metabolizing pathways in dogs with congenital portosystemic shunts.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">van Straten G, van Steenbeek FG, Grinwis GC, Favier RP, Kummeling A, van Gils IH, Fieten H, Groot Koerkamp MJ, Holstege FC, Rothuizen J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PLoS One. 2014; 9(6):e100077. Epub 2014 Jun 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15164414" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Genetic approach to prenatal diagnosis in urea cycle defects.</a><span class="source">[Prenat Diagn. 2004]</span><div class="brieflinkpop offscreen_noflow">Genetic approach to prenatal diagnosis in urea cycle defects.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Häberle J, Koch HG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Prenat Diagn. 2004 May; 24(5):378-83. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8464164" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Molecular basis of urea cycle disorders].</a><span class="source">[Nihon Rinsho. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Molecular basis of urea cycle disorders].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Matsuda I, Matsuura T, Hoshide R, Uchino T, Matsubasa T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nihon Rinsho. 1993 Feb; 51(2):520-4. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25039902" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diagnosis and treatment of urea cycle disorder in Japan.</a><span class="source">[Pediatr Int. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diagnosis and treatment of urea cycle disorder in Japan.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nakamura K, Kido J, Mitsubuchi H, Endo F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatr Int. 2014 Aug; 56(4):506-9. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301396" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301396" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041a17dde08911695b9a50">Urea Cycle Disorders Overview - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Urea Cycle Disorders Overview - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:25:27-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D374EE040FC0100000000049401AD&amp;ncbi_session=CE8D374EE041A171_1172SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1217%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1217&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1217/&amp;ncbi_pagename=Urea Cycle Disorders Overview - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D374EE041A171_1172SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>